MediNatura New Mexico, Inc. Issues Voluntary Nationwide Recall of ReBoost Nasal Spray Due to Microbial Contamination
FDA Approves First Gene Therapy Treatment for Wiskott-Aldrich Syndrome
FDA Approves First Gene Therapy Treatment for Wiskott-Aldrich Syndrome
http://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-wiskott-aldrich-syndrome
First Approval in Commissioner’s National Priority Voucher Pilot Program Strengthens Domestic Antibiotic Manufacturing Capacity
La OPS renueva el llamado a cerrar brechas de vacunación ante el resurgimiento de la tosferina en las Américas
Cristina Mitchell
9 Dec 2025
FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia
FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia
http://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-severe-aplastic-anemia
PAHO updates influenza situation in the Americas as the winter season advances in the Northern Hemisphere
Cristina Mitchell
8 Dec 2025
PAHO launches Regional Alliance to accelerate HIV elimination in the Americas
Oscar Reyes
5 Dec 2025
FDA Launches TEMPO: A First-of-Its-Kind Digital Health Pilot to Expand Access to Chronic Disease Technologies
FDA Launches TEMPO: A First-of-Its-Kind Digital Health Pilot to Expand Access to Chronic Disease Technologies
http://www.fda.gov/news-events/press-announcements/fda-launches-tempo-first-its-kind-digital-health-pilot-expand-access-chronic-disease-technologies
FDA Approves First CAR T-Cell Therapy for Marginal Zone Lymphoma In the US
FDA Approves First CAR T-Cell Therapy for Marginal Zone Lymphoma In the US
http://www.fda.gov/news-events/press-announcements/fda-approves-first-car-t-cell-therapy-marginal-zone-lymphoma-us